LENZ Therapeutics Inc
LENZ29.330USD
-0.630-2.10%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
835.91MMarket Cap
LossP/E TTM
More Details of LENZ Therapeutics Inc Company
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Company Info
Ticker SymbolLENZ
Company nameLENZ Therapeutics Inc
IPO dateJun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
Number of employees42
Security typeOrdinary Share
Fiscal year-endJun 25
Address- -
City- -
Stock exchangeNASDAQ Global Select Consolidated
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolLENZ
IPO dateJun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
Company Executives
Name
Name/Position
Position
Shareholding
Change
Marc Odrich
Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Shawn Olsson
Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
James Mccollum
James Mccollum
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Marc Odrich
Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Shawn Olsson
Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
12.15%
Ridgeback Capital Management, L.P.
6.84%
Point72 Asset Management, L.P.
6.60%
Other
47.09%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
12.15%
Ridgeback Capital Management, L.P.
6.84%
Point72 Asset Management, L.P.
6.60%
Other
47.09%
Shareholder Types
Shareholders
Proportion
Venture Capital
41.87%
Hedge Fund
24.75%
Investment Advisor
21.00%
Investment Advisor/Hedge Fund
11.47%
Individual Investor
2.76%
Research Firm
0.79%
Bank and Trust
0.13%
Pension Fund
0.05%
Insurance Company
0.02%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
244
29.26M
103.53%
-770.18K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
2023Q1
205
7.41M
89.08%
-2.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
4.18M
14.85%
--
--
May 07, 2025
Alpha Wave Global, LP
3.61M
12.83%
--
--
Apr 14, 2025
Versant Ventures
3.66M
12.99%
-884.80K
-19.48%
Jun 27, 2025
Ridgeback Capital Management, L.P.
1.95M
6.93%
--
--
Apr 14, 2025
Point72 Asset Management, L.P.
1.88M
6.69%
+1.03M
+120.91%
Apr 14, 2025
Paradigm BioCapital Advisors LP
1.42M
5.04%
-92.10K
-6.09%
Apr 14, 2025
The Vanguard Group, Inc.
1.20M
4.25%
+21.02K
+1.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.05M
3.73%
-14.66K
-1.38%
Mar 31, 2025
72 Investment Holdings, LLC
1.02M
3.62%
--
--
Mar 31, 2025
Sectoral Asset Management Inc.
977.25K
3.47%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Harbor Health Care ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
SPDR S&P Pharmaceuticals ETF
0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.59%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.07%
Avantis US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.05%
View more
Harbor Health Care ETF
Proportion0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.89%
SPDR S&P Pharmaceuticals ETF
Proportion0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.59%
iShares Micro-Cap ETF
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
iShares Biotechnology ETF
Proportion0.07%
Avantis US Small Cap Equity ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Date
Type
Ratio
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
